PALATIN TECHNOLOGIES, INC. Amortization of Debt Issuance Costs
PALATIN TECHNOLOGIES, INC. (PTN) reported Amortization of Debt Issuance Costs of $0 for the 12-month period ending 2021-06-30, per its 10-K filed 2021-09-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2021-09-28
- PALATIN TECHNOLOGIES, INC. amortization of debt issuance costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- PALATIN TECHNOLOGIES, INC. amortization of debt issuance costs for fiscal 2020 was $438.00, a 99.15% decline from fiscal 2019.
- PALATIN TECHNOLOGIES, INC. amortization of debt issuance costs for fiscal 2019 was $51.23K, a 70.81% decline from fiscal 2018.
- PALATIN TECHNOLOGIES, INC. amortization of debt issuance costs for fiscal 2018 was $175.49K, a 41.27% decline from fiscal 2017.
| Period end | Amortization of Debt Issuance Costs 12 month |
|---|---|
| 2021-06-30 | $0.00 10-K · filed 2021-09-28 |
| 2020-06-30 | $438.00 10-K · filed 2021-09-28 |
| 2019-06-30 | $51.23K 10-K · filed 2020-09-25 |
| 2018-06-30 | $175.49K 10-K · filed 2020-09-25 |
| 2017-06-30 | $298.79K 10-K · filed 2019-09-12 |
| 2016-06-30 | $327.48K 10-K · filed 2018-09-13 |
| 2015-06-30 | $87.09K 10-K · filed 2017-09-25 |
| 2014-06-30 | $0.00 10-K · filed 2016-09-19 |
| 2013-06-30 | $0.00 10-K · filed 2015-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |